The Nogo/Nogo Receptor (NgR) Signal Is Involved in Neuroinflammation through the Regulation of Microglial Inflammatory Activation*

Received for publication, July 10, 2015, and in revised form, October 2, 2015. Published, JBC Papers in Press, October 15, 2015, DOI 10.1074/jbc.M115.678326

Yinquan Fang†‡, Jun Yan†‡, Chenhui Li†, Xiao Zhou†, Lemeng Yao‡, Tao Pang†, Ming Yan†, Luyong Zhang†, Lei Mao‡§ and Hong Liao†‡

From the †Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, 24 Tongjiaxiang Street, Nanjing 210009, China, the ‡Department of Biophysics, Saarland University, Homburg 66421, Germany, and the §Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China

Background: NgR is expressed on microglia and regulates cell adhesion and migration behavior.

Results: Nogo/NgR signal induced the expression of proinflammatory factors in microglia through NF-κB and STAT3 signal pathways.

Conclusion: Nogo peptide could directly take part in CNS inflammatory process by influencing the expression of proinflammatory factors in microglia.

Significance: Nogo/NgR signal might be involved in multiple processes in various inflammation-associated CNS diseases.

Microglia have been proposed to play a pivotal role in the inflammatory response of the CNS by expressing a range of proinflammatory enzymes and cytokines under pathological stimuli. Our previous study has confirmed that Nogo receptor (NgR), an axon outgrowth inhibition receptor, is also expressed on microglia and regulates cell adhesion and migration behavior in vitro. In the present study, we further investigated the proinflammatory effects and possible mechanisms of Nogo on microglia in vitro. In this study, Nogo peptide, Nogo-P4, a 25-amino acid core inhibitory peptide sequence of Nogo-66, was used. We found that Nogo-P4 was able to induce the expression of inducible nitric-oxide synthase and cyclooxygenase-2 and the release of proinflammatory cytokines, including IL-1β, TNF-α, NO, and prostaglandin E2, in microglia, which could be reversed by NEP1–40 (Nogo-66(1–40) antagonist peptide), phosphatidylinositol-specific phospholipase C, or NgR siRNA treatment. After Nogo-P4 stimulated microglia, the phosphorylation levels of NF-κB and STAT3 were increased obviously, which further mediated microglia expressing proinflammatory factors induced by Nogo-P4. Taken together, we concluded that Nogo peptide could directly take part in CNS inflammatory process by influencing the expression of proinflammatory factors in microglia, which were related to the NF-κB and STAT3 signal pathways. Besides neurite outgrowth restriction, the Nogo/NgR signal might be involved in multiple processes in various inflammation-associated CNS diseases.

Nogo-A, a myelin-associated inhibitory molecule, plays an important role in various cellular and molecular events contributing to the failure of CNS axon regrowth and reconnection after transection (1). Nogo receptor (NgR) is a neuronal surface glycosylphosphatidylinositol-linked receptor, which binds with high affinity to Nogo-66 (2). Accumulating reports have demonstrated that interrupting the function of the Nogo-A/NgR signal on neurons enables the extension of axons over the insulated zone, which is beneficial for the regeneration of the neurite and the functional improvement of the injured CNS (3). Recently, increasing numbers of in vitro studies have identified the expression of NgR on immune cells, including macrophage (4), microglia (5), dendritic cells (6), and peripheral blood mononuclear cells (7), implying that NgR might play a more widespread role in neuroinflammation under a range of neurologic conditions.

CNS inflammation plays a significant role in the progression of numerous CNS diseases, including brain trauma, spinal cord injury, ischemia, and degenerative disorders, although the mechanisms are not yet fully understood (8–13). Microglia, the resident CNS macrophage-like cell, has been proposed to participate in the innate immune response in the CNS (14). Overactivated microglia causes uncontrolled inflammatory response, including the release of proinflammatory and/or cytotoxic factors, leading to neuronal damage and tissue injury (15–18).

Evidence from animal models has elucidated that the efflux of macrophage out of the sites of inflammation in peripheral nerves and the termination of inflammation are mediated by NgR (4). Our previous work also demonstrated that NgR is expressed on microglia, and binding of NgR with Nogo-66...
Nogo/NgR Signal Involved in Neuroinflammation

inhibits the adhesion and migration of microglia (5), suggesting that NgR will possibly take part in neuroinflammation via mediating microglia adhesion and migration. So far, although several reports have implied the relationship between the Nogo-A signal and CNS inflammation, there is few direct evidence and mechanisms associated with the role of Nogo in neuroinflammation have been provided. In the present study, we explored the effects of Nogo-P4 on the expression of inflammatory mediators in microglia, including iNOS, COX-2, IL-1β, TNF-α, NO, and PGE₂. Nogo-P4 is a 25-amino acid inhibitory peptide

Experimental Procedures

Cell Culture and Treatments—Sprague-Dawley rats were purchased from Zhejiang Laboratory Animal Center (Hangzhou, China). All animal tests were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All experimental procedures were approved by the institutional animal care and use committee of the Nanjing Medical University Experimental Animal Department.

Primary microglia culture was prepared following the method described previously with some modifications (5). Briefly, cerebral cortex from postnatal Sprague-Dawley rats (P0–P2) was stripped of meninges and chopped into small chunks. The tissue was then dissociated in trypsin-EDTA (P0–P2) was stripped of meninges and chopped into small chunks. The tissue was then dissociated in trypsin-EDTA (P0–P2) was stripped of meninges and chopped into small chunks. The tissue was then dissociated in trypsin-EDTA (P0–P2) was stripped of meninges and chopped into small chunks. The tissue was then dissociated in trypsin-EDTA (P0–P2) was stripped of meninges and chopped into small chunks. The tissue was then dissociated in trypsin-EDTA (P0–P2) was stripped of meninges and chopped into small chunks. The tissue was then dissociated in trypsin-EDTA (P0–P2) was stripped of meninges and chopped into small chunks. The tissue was then dissociated in trypsin-EDTA (P0–P2) was stripped of meninges and chopped into small chunks. The tissue was then dissociated in trypsin-EDTA

Western Blot Analysis—Microglia obtained from different treatments were lysed in ice-cold lysis buffer (50 mM Tris-HCl, 2 mM MgCl₂, 1% Nonidet P-40, 10% glycerol, 100 mM NaCl), and 1% protease inhibitor mixture (Roche Applied Science) was added just before use. The lysates were cleared by centrifugation at 13,000 × g for 10 min at 4 °C. Supernatant protein (50 μg) was run in denaturing gels and transferred onto nitrocellulose membranes. The membranes were then blocked with 5% bovine serum albumin in TBST and incubated with specific primary antibody overnight at 4 °C. The following antibodies were used: goat anti-IL-1β (1:500; R&D Systems, AF-501-NA), rabbit anti-iNOS (1:1000; Abcam, ab3523), goat anti-COX-2 (1:500; Santa Cruz Biotechnology, sc-1747), rabbit anti-NgR (1:1000; Merck Millipore, AB 15138), rabbit anti-phospho-NF-κB p65 at Ser-536 (1:1000; Cell Signaling Technology Inc., catalog no. 3033), rabbit anti-NF-κB p65 (1:1000; Cell Signaling Technology Inc., catalog no. 8242), rabbit anti-phospho-IKBβ
Nogo/NgR Signal Involved in Neuroinflammation

Results

Stimulation with Nogo-P4 Increased Microglia Expressing iNOS and COX-2 as Well as Releasing IL-1β, TNF-α, NO, and PGE₂—To investigate the effects of Nogo-P4 on the production of proinflammatory enzymes and cytokines in microglia, wells were precoated with Nogo-P4 (100 μg/ml) or Rtn-P4 (100 μg/ml), and then primary cultured microglia were added into the wells and cultured for 6, 12, or 24 h. At the end of stimulation, the cell lysates and supernatants were collected, and the expression levels of proinflammatory enzymes and cytokines were determined. Results in Fig. 1 showed that Nogo-P4 stimulation significantly promoted microglia to express iNOS (12 and 24 h) and COX-2 (6 and 12 h) and also raised the release of IL-1β (12 h), TNF-α (6 and 12 h), PGE₂ (12 h), and NO (12 h) in microglia. However, Rtn-P4 had no effects. Thus, a 12 h stimulation time was used for the following study. Moreover, full-length Nogo-66 increased the expression of IL-1β and NO in microglia (data not shown). These results implied that Nogo peptide could directly participate in inflammation associated with microglia by increasing the expression of proinflammatory enzymes and cytokines in microglia.

NgR Was Responsible for the Effects of Nogo-P4 on Microglia Producing Proinflammatory Mediators—The glycosylphosphatidylinositol-linked cell surface NgR has been widely confirmed to be the Nogo-66 functional receptor to inhibit neurite growth (2) as well as neural cell migration (5, 22). To elucidate the possible signal pathway related to Nogo-P4, we assessed the mediation of NgR on Nogo-P4 facilitating proinflammatory cytokine production. The expression of NgR on primary cultured microglia has already been clearly identified in our previous study (5); thus, we pretreated microglia with NEP1–40 (10 μM) and the PI-PLC (0.3 units/ml) and then observed the effects of Nogo-P4 on expressing proinflammatory enzymes and cytokines. NEP1–40, a competitive antagonist peptide derived from the first 40 amino acids of the Nogo-66, promotes axonal outgrowth through blocking the binding of Nogo-66 to NgR in vitro and in vivo (23). PI-PLC is commonly used to release the glycosylphosphatidylinositol-anchored NgR from the cell surface (2). As seen in Fig. 2, the results showed that NEP1–40 and PI-PLC treatment significantly attenuated the expression of pro-IL-1β, iNOS, and COX-2 as well as the release of IL-1β, NO, and PGE₂ in microglia after Nogo-P4 stimulation, indicating that NgR was necessary for the effects of Nogo-P4 on the production of proinflammatory mediators in microglia.

Furthermore, NgR was silenced by siRNA interference in BV-2 microglia, and the expression of proinflammatory mediators was analyzed. After transfection with NgR siRNA or control siRNA, the expression of NgR was determined by Western blot. Compared with control siRNA-treated cells, NgR siRNA-treated cells showed a significant decrease of the expression of NgR in BV-2 microglial cells (Fig. 3, A and B). Also, the transfection of control or NgR siRNA did not affect the cellular ability of BV-2 microglial cells (Fig. 3C). Results shown in Fig. 3, D–I, showed that NgR siRNA treatment significantly attenuated the expression of iNOS and COX-2 as well as the release of IL-1β, NO, and TNF-α in microglia after Nogo-P4 stimulation, indicating that NgR was responsible for...
FIGURE 1. Stimulation with Nogo-P4 increased the expression of inflammatory mediators in primary cultured microglia. Microglia separated from the cerebral cortex were seeded into wells precoated with PBS or Rtn-P4 (100 μg/ml) or Nogo-P4 (100 μg/ml) and stimulated for 6, 12, or 24 h. Cell lysates and supernatant were collected to detect the expression of inflammatory mediators. Western blot was used to determine the expression of iNOS (A and B) and COX-2 (C and D). Values are reported as mean ± S.D. (error bars), as a percentage of values determined in the PBS group (control, 100%). The Western blot data represent the results of four independent experiments. The Griess method was performed to detect NO release (E). The proportions of PGE₂ (F), IL-1β (G), and TNF-α (H) secreted into the medium was assayed by ELISA kits. Values are reported as mean ± S.D. Griess and ELISA data represent the results of three independent experiments. Statistical analysis was performed using one-way ANOVA with post hoc Tukey's test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
the effects of Nogo-P4 on the expression of proinflammatory mediators in BV-2 microglial cells.

Microglia Expressing Proinflammatory Mediators Induced by Nogo-P4 Was Mediated by NF-κB Pathway Activation via NgR—The nuclear factor NF-κB pathway has long been considered as a prototypical proinflammatory signal pathway (24). Thus, we investigated whether the NF-κB pathway was responsible for the effects of Nogo-P4 on the production of proinflammatory mediators in microglia. Microglia were seeded into the wells precoated with Nogo-P4, and then cell lysates were collected for Western blot. We observed a significant increase in the phosphorylation levels of NF-κB, IKKβ, and IκBα in microglia after stimulation by Nogo-P4 for 6 h (Fig. 4, A–F). In addition, Immunofluorescent staining analysis showed that Nogo-P4 induced NF-κB nuclear translocation in microglia (Fig. 4, G and H).

Furthermore, we determined whether NgR mediated NF-κB pathway activation induced by Nogo-P4. Before they were added to the protein-coated plate, microglia were pretreated with NEP1–40 (10 μM) or PI-PLC (0.3 units/ml) for 30 min to interrupt the function of NgR. The cells were then exposed to PBS or Nogo-P4 for 12 h. The proportions of iNOS (A and B), pro-IL-1β (C and D), and COX-2 (C and E) were determined by Western blot. Values are reported as mean ± S.D. (error bars), as a percentage of values determined in the PBS group (control, 100%). The release of NO was assayed by the Griess method (F). An ELISA was performed to detect the production of PGE2 (G) and IL-1β (H) in the supernatant. Values are reported as mean ± S.D. All data represent the results of three independent experiments. Statistical analysis was performed using Student’s t test. *, p < 0.05; **, p < 0.01.
NF-κB nuclear translocation in microglia was significantly inhibited by NEP1–40. (Fig. 5, G and H). The results above indicated that Nogo-P4 bound to the NgR receptor and further triggered the activation of the NF-κB pathway.

To validate whether the activation of NF-κB pathway was a response to the expression of proinflammatory cytokines induced by Nogo-P4, JSH-23 (an NF-κB activation inhibitor), which could inhibit nuclear translocation of NF-κB (25), was used to block the
activity of the NF-κB signal pathway. We found that the nuclear translocation of NF-κB increased by Nogo-P4 was blocked in microglia pretreated with JSH-23 (10 μM) for 30 min (Fig. 6, A and B). Results presented in Fig. 6, C–I, indicated that promotion of Nogo-P4 upon microglial expression of iNOS and COX-2 as well as the release of IL-1β, TNF-α, NO, and PGE2 was attenuated by JSH-23 (10 μM) pretreatment, suggesting that the NF-κB pathway was responsible for the effects of the Nogo/NgR signal on microglia expressing proinflammatory mediators.

**STAT3 Signal Pathway Involved in Microglia Expressing Proinflammatory Mediators Induced by Nogo-P4 via NgR**—The STAT3 signal pathway has been shown to play roles in the inflammatory signaling cascades in response to several immune stimulations. Thus, we next investigated whether STAT3 signal pathway acted as the intracellular signal transducer to mediate the release of proinflammatory cytokines in microglia after Nogo-P4 stimulation. Microglia were seeded into the wells pre-coated with Nogo-P4, and then cells were collected for STAT3 activity detection. It was observed that Nogo-P4 significantly increased the STAT3 tyrosine phosphorylated at residue Tyr-705 (Fig. 7, A and B). Furthermore, the activation of the STAT3 pathway was greatly attenuated after the function block of NgR with NEP1–40 or PI-PLC (Fig. 7, C and D). The results above implied that Nogo-P4 bound to the NgR receptor and further triggered the phosphorylation of STAT3.

To validate whether the activation of STAT3 pathway was a response to the expression of proinflammatory cytokines induced by Nogo-P4, S3I-201, an inhibitor of STAT3 (26), was used to block the activity of the STAT3 signal pathway. S3I-201 (20 μM) lowered the phosphorylation of STAT3 induced by Nogo-P4 (Fig. 7, E and F). Results presented in Fig. 8 showed that S3I-201 (20 μM) pretreatment abolished the expression of iNOS and COX-2 as well
as the release of IL-1β, TNF-α, NO, and PGE₂ in microglia increased by Nogo-P4, suggesting that the STAT3 signal pathway might take part in microglia expressing proinflammatory cytokines in response to Nogo/NgR signal.

The Relationship between NF-κB and STAT3 Signal Pathway after Nogo-P4 Activated Microglia—We confirmed that both the NF-κB signal pathway and the STAT3 signal pathway were involved in the expression of proinflammatory mediators in microglia induced by Nogo-P4. But what is the relationship between the NF-κB signal pathway and the STAT3 signal pathway? We still do not know. Thus, we pretreated microglia with S3I-201 (20 μM; a STAT3 activation inhibitor) or JSH-23 (10 μM; an NF-κB activation inhibitor) for 30 min to investigate the relationship between the NF-κB pathway and the STAT3 path-
The phosphorylation of NF-κB induced by Nogo-P4 was blocked after microglia were pretreated with S3I-201 (Fig. 9, A and B). However, the phosphorylation of STAT3 induced by Nogo-P4 was not affected after microglia were pretreated with JSH-23 (Fig. 9, C and D). These data suggested that the NF-κB pathway, possibly be downstream of the STAT3 pathway, mediated the effects of Nogo-P4 on the expression of proinflammatory mediators in microglia.
Discussion

Our results indicated that Nogo peptide elevated the production of proinflammatory cytokines of microglia in vitro, which was mediated by NF-κB and STAT3 signal pathways. From the results presented above, two points are particularly noteworthy. First, the results from our in vitro study confirmed that Nogo-P4 (the 25-amino acid inhibitory peptide sequence of Nogo-66) elevated the expression of proinflammatory cytokines in microglia. Nogo-P4, corresponding to residues 31–55 of the extracellular fragment of Nogo-66, significantly inhibits the neurite outgrowth and exhibits significant growth cone-collapsing activity in vitro (27–29). In many CNS disorders, such as multiple sclerosis (MS) and Alzheimer disease (AD), chronic inflammation is one of the main pathologic features (30). Chronic inflammatory processes in MS lead to neuronal injury as well as neurodegeneration (31). There is also evidence that the expression of Nogo-A is significantly up-regulated during MS (32), and Nogo-A could participate in the inflammation process of MS (33). In AD, chronic inflammatory is not a passive system activated by emerging senile plaques and neurofibrillary tangles but instead contributes more to pathogenesis than to plaques and tangles themselves (34). Moreover, Nogo-A is overexpressed by hippocampal neurons in AD and is associated with Aβ-amyloid deposits in senile plaques (35). Hence,

FIGURE 6. Microglia expressing proinflammatory mediators induced by Nogo-P4 was mediated by the NF-κB pathway. Before they were added to the protein-coated plate, microglia were pretreated with JSH-23 (10 μM) for 30 min to interrupt the activation of NF-κB. Microglia were incubated with PBS or Nogo-P4 for 6 h, and cell lysates were collected to detect the phosphorylation level of STAT3. Values are reported as mean ± S.D. (error bars) Statistical analysis was performed using Student’s t test. C and D, activation of STAT3 pathway induced by Nogo-P4 was mediated by NgR. Microglia were pretreated with NEP1–40 (10 μM) or PI-PLC (0.3 units/ml) for 30 min in order to block the interaction of Nogo-P4 with NgR before the phosphorylation level of STAT3 was determined. Values are reported as mean ± S.D. E and F, S3I-201 blocked the phosphorylation of STAT3 activated by Nogo-P4. Microglia were pretreated with S3I-201 (20 μM) for 30 min before cells were cultured to determine the phosphorylation of STAT3. Values are reported as mean ± S.D. All data represent the results of three independent experiments. Statistical analysis was performed using one-way ANOVA with post hoc Tukey’s test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

FIGURE 7. Activation of STAT3 pathway by Nogo-P4 was blocked by S3I-201. A and B, Nogo-P4 induced the phosphorylation of STAT3. Microglia were incubated with PBS or Nogo-P4 for 6 h, and cell lysates were collected to detect the phosphorylation level of STAT3. Values are reported as mean ± S.D. (error bars) Statistical analysis was performed using Student’s t test. C and D, activation of STAT3 pathway induced by Nogo-P4 was mediated by NgR. Microglia were pretreated with NEP1–40 (10 μM) or PI-PLC (0.3 units/ml) for 30 min in order to block the interaction of Nogo-P4 with NgR before the phosphorylation level of STAT3 was determined. Values are reported as mean ± S.D. E and F, S3I-201 blocked the phosphorylation of STAT3 activated by Nogo-P4. Microglia were pretreated with S3I-201 (20 μM) for 30 min before cells were cultured to determine the phosphorylation of STAT3. Values are reported as mean ± S.D. All data represent the results of three independent experiments. Statistical analysis was performed using one-way ANOVA with post hoc Tukey’s test. **, p < 0.01; ***, p < 0.001.
might the potentiated effects of Nogo peptide contribute to chronic inflammatory processes and furthermore be involved in pathogenesis of chronic inflammatory diseases? Our results showed that Nogo-P4 could induce microglial expression of proinflammatory mediators, and blocking the binding of Nogo-P4 to NgR on microglia by NEP1–40 or PI-PLC pretreatment or silencing the expression of NgR by siRNA interference rescued the increased expression of proinflammatory mediators induced by Nogo-P4, indicating that NgR was necessary for the effects of Nogo-P4 on microglia expressing proinflammatory mediators.

Second, we also verified that the activation of the NF-κB pathway and STAT3 pathway was responsible for the effects of the Nogo/NgR signal on the expression of proinflammatory mediators in microglia. It is well established that NF-κB and STAT3 are transcription factors that participate in cytokine and growth factor actions in immune cells and transcription of a variety of genes involved in inflammation, cellular adaptation to stress, and cell death (36). Activated IKKβ phosphorylates IκB and triggers its degradation by proteasomes, and this process results in translocation of NF-κB to the nucleus and the induction of NF-κB-dependent transcription of a wide range of immune and inflammatory genes (37). Recently, research has found that the NF-κB signal pathway is central to many macrophage (25) and microglial functions, including phagocytosis and cytokine secretion. Moreover, strong microglial NF-κB pathway activation has been described

![Image of Figure 8](https://example.com/figure8.png)

**FIGURE 8.** **STAT3 pathway was involved in Nogo-P4 triggered proinflammatory mediators expressing.** Microglia were pretreated with S3I-201 (20 μM), an inhibitor of the activation of STAT3 pathway, for 30 min and then exposed to either PBS or Nogo-P4 for 12 h. The expression level of iNOS (A and B) and COX-2 (C and D) was determined by Western blot assay. Values are reported as mean ± S.D. (error bars), as a percentage of values determined in the PBS group (control, 100%). Western blot data represent the results of four independent experiments. Release of NO was assayed by the Griess method (E). ELISA was performed to detect the production of PGE₂ (F), IL-1β (G), and TNF-α (H) in supernatant. Values are reported as mean ± S.D. Griess and ELISA data represent the results of three independent experiments. Statistical analysis was performed using one-way ANOVA with post hoc Tukey’s test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
following lipopolysaccharide (LPS) treatment in vitro (38) and in pathological situations that involve strong inflammatory processes and massive peripheral blood cell recruitment, such as MS (39), experimental autoimmune encephalitis (40), and spinal cord injury (41). STAT3 tyrosine phosphorylated at residue Tyr-705 translocates to the nucleus, where it binds to specific promoter sequences of several inflammation associated genes, thus playing a central role in regulating the expression of a series of proinflammatory cytokines. It is reported that the STAT3 pathway is involved in the function of Nogo/NgR on the fate decision of neural precursor differentiation (42). The present study demonstrated that the NF-κB and STAT3 pathways contributed to the inflammatory response by directly modifying the expression of inflammatory mediators in microglia after Nogo-P4 stimulation.

Both the STAT3 pathway and the NF-κB pathway are critical transcription factors involved in the inflammatory processes of many CNS diseases. The STAT3 pathway and NF-κB pathway regulate the expression of target genes, such as inflammatory genes, individually or cooperatively. For example, it has been reported that curcumin ameliorates the depressed MFG-E8 expression and the attenuated phagocytic ability of EMF-exposed N9 cells, which is attributable to the inhibition of the proinflammatory response through the NF-κB and STAT3 pathways (43). Moreover, hydroxysafflor yellow A protected Aβ(1–42)-induced AD model through inhibiting inflammatory response, which may involve the JAK2/STAT3/NF-κB pathway (44). In the present study, our results demonstrated that S3I-201, an inhibitor for STAT3, reversed the activation of the NF-κB pathway induced by Nogo-P4, suggesting that the NF-κB pathway might be downstream of the STAT3 pathway to mediate the promotion of microglia expressing proinflammatory mediators stimulated by Nogo-P4.

Conclusions

Our present study has demonstrated that exposing the Nogo peptide to microglia elevated the expression of proinflammatory enzymes and cytokines in vitro, which was mediated by the NF-κB and STAT3 pathways. These results imply that the interaction of Nogo peptide with NgR expressed on microglia might participate in diverse CNS diseases related to chronic neuroinflammation, such as neurodegenerative diseases.

Author Contributions—Y. Q. F., J. Y., C. H. L., L. M., H. L., L. Y. Z., and M. Y. conceived and designed the experiments. Y. Q. F., J. Y., L. M. Y., and X. Z. performed the experiments. Y. Q. F., J. Y., C. H. L., H. L., L. Y. Z., and T. P. analyzed and interpreted the data and wrote the paper. All authors analyzed the results and approved the final version of the manuscript.

References

1. He, Z., and Koprivica, V. (2004) The Nogo signaling pathway for regeneration block. Annu. Rev. Neurosci. 27, 341–368
2. Fournier, A. E., GrandPre, T., and Strittmatter, S. M. (2001) Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 409, 341–346
their migration. J. Cell Sci. 120, 1877–1887
23. GrandPré, T., Li, S., and Strittmatter, S. M. (2002) Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 417, 547–551
24. Lawrence, T. (2009) The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1, a001651
25. Ren, S., Zhang, S., Li, M., Huang, C., Liang, R., Jiang, A., Guo, Y., Pu, Y., Huang, N., Yang, J., and Li, Z. (2013) NF-κB p65 and c-Rel subunits promote phagocytosis and cytokine secretion by splenic macrophages in cirrhotic patients with hypersplenism. Int. J. Biochem. Cell Biol. 45, 335–343
26. Siddiquie, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L., Jove, R., McLaughlin, M. M., Lawrence, N. J., Sebti, S. M., and Turkson, J. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces anti-tumor activity. Proc. Natl. Acad. Sci. U.S.A. 104, 7391–7396
27. Yamashita, T., and Tohyama, M. (2003) The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat. Neurosci. 6, 461–467
28. Hasegawa, Y., Fujitani, M., Hata, K., Tohyama, M., Yamagishi, S., and Yamashita, T. (2004) Promotion of axon regeneration by myelin-associated glycoprotein and Nogo through divergent signals downstream of G(i)/G(j). J. Neurosci. 24, 6826–6832
29. Rolando, C., Parolis, R., Boda, E., Schwab, M. E., Rossi, F., and Buffo, A. (2012) Distinct roles of Nogo-a and Nogo receptor 1 in the homeostatic regulation of adult neural stem cell function and neuroblast migration. J. Neurosci. 32, 17784–17799
30. Lucas, S. M., Rothwell, N. J., and Gibson, R. M. (2006) The role of inflammation in CNS injury and repair. Br. J. Pharmacol. 147, S232–S240
31. Zindler, E., and Zipp, F. (2010) Neuronal injury in chronic CNS inflammation. Best Pract. Res. Clin. Anaesthesiol. 24, 551–562
32. Satoh, J., Onoue, H., Arima, K., and Yamamura, T. (2005) Nogo-A and nogo receptor expression in demyelinating lesions of multiple sclerosis. J. Neuropathol. Exp. Neurol. 64, 129–138
33. Fontoura, P., Ho, P. P., Devoss, J., Zheng, B., Lee, B. J., Kidd, B. A., Garren, H., Sobel, R. A., Robinson, W. H., Tessler-Lavigne, M., and Steinman, L. (2004) Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J. Immunol. 173, 6981–6992
34. Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Broserson, F., Feinsein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Lutz, E., Halle, A., Petzold, G. C., Town, T., Morgan, D., Shinohara, M. L., Perry, V. H., Holmes, C., Bazan, N. G., Brooks, D. J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarolo, C. A., Breitner, J. C., Cole, G. M., Golenbock, D. T., and Kummer, P. M. (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14, 388–405
35. Gil, V., Nicolas, O., Mingorance, A., Ureña, J. M., Tang, B. L., Hirata, T., Sáez-Valero, J., Ferrer, I., Soriano, E., and del Río, J. A. (2006) Nogo-A expression in the human hippocampus in normal aging and in Alzheimer disease. J. Neuropathol. Exp. Neurol. 65, 433–444
36. Acarin, L., González, B., and Castellano, B. (2000) STAT3 and NF-κB activation precedes glial reactivity in the excitotoxic injury in cortex but not in the corresponding distal thalamic nuclei. J. Neurophatol. Exp. Neurol. 59, 151–163
37. Liu, Y., Liu, X., Hao, W., Decky, Y., Schomberg, R., Fülop, L., Pasparakis, M., Menger, M. D., and Fassbender, K. (2014) IKKβ deficiency in myeloid cells ameliorates Alzheimer’s disease-related symptoms and pathology. J. Neurosci. 34, 12982–12999
38. Heese, K., Fiebich, B. L., Bauer, J., and Otten, U. (1998) NF-κB modulates lipopolysaccharide-induced microglial nerve growth factor expression. Glia 22, 401–407
39. Gveric, D., Kaltenschmidt, C., Cuzner, M. L., and Newcombe, J. (1998) Transcription factor NF-κB and inhibitor IκBα are localized in macrophages in active multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 57, 168–178
40. Kaltenschmidt, C., Kaltenschmidt, B., Lannes-Vieira, J., Kreutzberg, G. W., Wekerle, H., Baeuerle, P. A., and Gehrmann, J. (1994) Transcription factor NF-κB is activated in microglia during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 55, 99–106
41. Bethea, J., Castro, M., Keane, R. W., Lee, T. T., Dietrich, W. D., and Yezier...
ski, R. P. (1998) Traumatic spinal cord injury induces nuclear factor-κB activation. J. Neurosci. 18, 3251–3260
42. Wang, B., Xiao, Z., Chen, B., Han, J., Gao, Y., Zhang, J., Zhao, W., Wang, X., and Dai, J. (2008) Nogo-66 promotes the differentiation of neural progenitors into astroglial lineage cells through mTOR-STAT3 pathway. PLoS One 3, e1856
43. He, G. L., Liu, Y., Li, M., Chen, C. H., Gao, P., Yu, Z. P., and Yang, X. S. (2014) The amelioration of phagocytic ability in microglial cells by curcumin through the inhibition of EMF-induced pro-inflammatory responses. J. Neuroinflammation 11, 49
44. Zhang, Z. H., Yu, L. J., Hui, X. C., Wu, Z. Z., Yin, K. L., Yang, H., and Xu, Y. (2014) Hydroxy-safflor yellow A attenuates Aβ(1–42)-induced inflammation by modulating the JAK2/STAT3/NF-κB pathway. Brain Res. 1563, 72–80